Our team of hepatologists, nurse practitioners, and physician assistants treat patients with a variety of complex liver conditions. Here are a few multidisciplinary clinics that are offered to serve the unique needs of our patient populations.
A rare genetic condition that often affects the liver and heart, Alagille Syndrome is usually diagnosed within the first few year's of a child's life. Under the medical direction of Dr. Noelle Ebel, our Alagille Syndrome Program brings together experts from the Betty Irene Moore Children’s Heart Center, Pulmonary Artery Reconstruction (PAR) Program, Pediatric Transplant Center and Neurosurgery program to make sure that children with this rare disease get the specialized treatment they require.
When one of the two heart ventricles does not develop fully, the heart has diffculty pumping blood throughout the whole body. Our Single Ventricle Program brings together a team of experts representing the many organ systems affected to help care for children with this rare, congenital heart disease.
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a disease of the bile ducts. The bile ducts become inflammed or blocked, allowing bile to accumulate in the liver. Some patients with PSC are also diagnosed with inflammatory bowel disease. In these cases, our hepatologists work closely with the IBD Center to determine treatment.
Through involvement in clinical registries, outcomes research, and investigational trials, the hepatology team seeks to advance the medical science and better understand the mechanisms that cause liver diseases as well as the indicators for better response to different treatments.
Here we highlight clinical projects that are currently recruiting or are about to begin. Visit our Publications and Presentations page to view a list of recently presented research findings.
The BOLD Study
Stanford is proud to be one of two recruiting sites in California for the Biliary Atresia and the Use of Odevixibat in Treating Liver Disease (BOLD) study. Under the direction of site investigator Dr. Amrita Narang, the trial will evaluate if a child with biliary atresia who has undergone a Kasai hepatoportoenterostomy can delay or avoid liver transplant by taking the investigational drug odevixibat. The BOLD study is the first pivotal Phase 3 clinical trial for infants with biliary atresia.
Find out more information at https://clinicaltrials.gov/ct2/show/NCT04336722.
We are proud to be involved with multiple networks and organizations dedicated to the care of children with acute and chronic liver conditions. Below you can see some of our recent national presentations.
Patient Webinar: Biliary Atresia (Liver Disease) in Children
October 9, 2021 | Stanford Children's Health
Pediatric Liver Disease and COVID-19
January 27, 2021 | American Liver Foundation
COVID-19 and the liver: pediatric perspective
July 23, 2020 | AASLD-NASPGHAN-SPLIT
Frontline Report: COVID-19 in Children
June 1, 2020 | Autoimmune Hepatitis Association